Tema Etfs LLC Makes New $1.60 Million Investment in Edwards Lifesciences Co. (NYSE:EW)

Tema Etfs LLC bought a new stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 21,635 shares of the medical research company's stock, valued at approximately $1,602,000.

Several other institutional investors and hedge funds also recently bought and sold shares of EW. Norges Bank purchased a new stake in Edwards Lifesciences during the 4th quarter valued at approximately $610,895,000. Jennison Associates LLC purchased a new position in Edwards Lifesciences in the fourth quarter worth about $555,939,000. Vanguard Group Inc. lifted its holdings in shares of Edwards Lifesciences by 10.4% in the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company's stock worth $5,117,845,000 after acquiring an additional 6,537,494 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Edwards Lifesciences during the 4th quarter worth about $213,844,000. Finally, Marshall Wace LLP grew its holdings in Edwards Lifesciences by 55.7% during the 4th quarter. Marshall Wace LLP now owns 5,813,419 shares of the medical research company's stock valued at $430,367,000 after purchasing an additional 2,079,642 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Down 2.2%

EW stock traded down $1.69 during trading on Wednesday, reaching $76.14. 4,412,954 shares of the company traded hands, compared to its average volume of 5,126,454. The company has a market capitalization of $44.66 billion, a price-to-earnings ratio of 10.92, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The business has a 50 day simple moving average of $72.47 and a 200 day simple moving average of $71.90. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $95.25. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The firm had revenue of $1.41 billion during the quarter, compared to analysts' expectations of $1.40 billion. During the same quarter last year, the firm earned $0.66 EPS. The business's quarterly revenue was up 6.2% on a year-over-year basis. On average, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $70.78, for a total transaction of $796,275.00. Following the completion of the sale, the chief financial officer now directly owns 30,387 shares in the company, valued at approximately $2,150,791.86. The trade was a 27.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Bernard J. Zovighian sold 6,164 shares of Edwards Lifesciences stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $69.51, for a total value of $428,459.64. Following the transaction, the chief executive officer now owns 59,083 shares of the company's stock, valued at $4,106,859.33. The trade was a 9.45% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 66,192 shares of company stock worth $4,709,454. Company insiders own 1.29% of the company's stock.

Analyst Ratings Changes

Several brokerages have issued reports on EW. Morgan Stanley raised their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a research note on Wednesday, February 12th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Piper Sandler lifted their target price on Edwards Lifesciences from $80.00 to $83.00 and gave the stock an "overweight" rating in a research report on Tuesday, May 13th. Barclays boosted their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. Finally, StockNews.com lowered shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a report on Friday, May 16th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $79.60.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.